Anaphylaxis in patients with congenital bleeding disorders and inhibitors

Anaphylactic reactions are rare emergencies observed in patients with inherited bleeding disorders. When these adverse events occur in patients with inhibitors, they further complicate the management of an already challenging clinical situation. Anaphylactoid inhibitors have been reported in patients with inhibitors associated with hemophilia A, hemophilia B, and type 3 von Willebrand disease. In this review, we summarize the current literature data on the occurrence of anaphylactoid reactions in patients with inherited bleeding disorders and alloantibodies. In particular, we focus on the pathophysiology of the inhibitor development and its management.

[1]  J. Freedman,et al.  Plasma-derived biological medicines used to promote haemostasis , 2008, Thrombosis and Haemostasis.

[2]  A. Chuansumrit,et al.  The use of rituximab as an adjuvant for immune tolerance therapy in a hemophilia B boy with inhibitor and anaphylaxis to factor IX concentrate , 2008, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[3]  A. Giuffrida,et al.  Treatment for patients with type 3 von Willebrand disease and alloantibodies: a case report , 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

[4]  I. Warrier.  Factor IX Inhibitors and Anaphylaxis , 2008 .

[5]  P. Giangrande,et al.  Achievement of immune tolerance in a patient with haemophilia B and inhibitory antibodies, complicated by an anaphylactoid reaction , 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

[6]  N. Hunzelmann,et al.  IgE‐mediated anaphylactic reaction to purified and recombinant factor VIII in a patient with severe haemophilia A , 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

[7]  J. Saint-Remy,et al.  Factor VIII alloantibodies in hemophilia , 2004, Current opinion in hematology.

[8]  M. Shima,et al.  Management of haemophilia B inhibitor patients with anaphylactic reactions to FIX concentrates , 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

[9]  M. Wolf,et al.  Multi‐therapeutic approach to manage delivery in an alloimmunized patient with type 3 von Willebrand disease , 2003, Journal of thrombosis and haemostasis : JTH.

[10]  C. Barnes,et al.  Induction of immune tolerance and suppression of anaphylaxis in a child with haemophilia B by simple plasmapheresis and antigen exposure: progress report , 2001, Haemophilia : the official journal of the World Federation of Hemophilia.

[11]  C. Barnes,et al.  Induction of immune tolerance and suppression of anaphylaxis in a child with haemophilia B by simple plasmapheresis and antigen exposure , 2000, Haemophilia : the official journal of the World Federation of Hemophilia.

[12]  R. Grossmann,et al.  Continuous Infusion of Recombinant Factor VIIa (NovoSeven®) in the Treatment of a Patient with Type III von Willebrand’s Disease and Alloantibodies against von Willebrand Factor , 2000, Thrombosis and Haemostasis.

[13]  A. Houllier,et al.  Mapping and Functional Studies of Two Alloantibodies Developed in Patients with Type 3 von Willebrand Disease , 2000, Thrombosis and Haemostasis.

[14]  B. Polack,et al.  Anaphylaxis following the use of a plasma‐derived immunopurified Monoclate‐P®, and the recombinant Recombinate® and Kogenate® factor VIII: a therapeutic challenge , 1999, Haemophilia : the official journal of the World Federation of Hemophilia.

[15]  E. Thorland,et al.  Anaphylactic response to factor IX replacement therapy in haemophilia B patients: complete gene deletions confer the highest risk. , 1999, Haemophilia : the official journal of the World Federation of Hemophilia.

[16]  R. Ljung,et al.  Anaphylactoid reactions and nephrotic syndrome – a considerable risk during factor IX treatment in patients with haemophilia B and inhibitors: a report on the outcome in two brothers , 1998, Haemophilia : the official journal of the World Federation of Hemophilia.

[17]  C. Kessler,et al.  Management of haemophilia B patients with inhibitors and anaphylaxis , 1998, Haemophilia : the official journal of the World Federation of Hemophilia.

[18]  R. Geha,et al.  IgE-mediated allergy and desensitization to factor IX in hemophilia B. , 1998, The Journal of allergy and clinical immunology.

[19]  M. Shima,et al.  Anaphylactic response to factor VIII preparations in a haemophilic child with an inhibitor of high titre during the tolerance induction , 1998, European Journal of Pediatrics.

[20]  I. Warrier,et al.  Development of anaphylactic shock in haemophilia B patients with inhibitors. , 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[21]  J. Batlle,et al.  Alloantibody from a patient with severe von Willebrand disease inhibits von Willebrand factor-FVIII interaction , 1997, Annals of Hematology.

[22]  I. Warrier,et al.  F, Spiro I: Posttransplantation lymphoproliferative disorders in solid Nephrotic Syndrome as a Complication of Immune Tolerance in Hemophilia B , 1997 .

[23]  M. Shima,et al.  Measurement of anti-factor IX IgG subclasses in haemophilia B patients who developed inhibitors with episodes of allergic reactions to factor IX concentrates. , 1996, Thrombosis research.

[24]  J. Giddings,et al.  Protective effects of ticlopidine and aspirin, administered alone and in combination, on thrombus formation in rat cerebral vessels. , 1996, Haemostasis.

[25]  D. Brettler,et al.  Anaphylaxis after treatment with recombinant factor VIII , 1996, Transfusion.

[26]  A. Federici,et al.  Posttransfusion anaphylactic reactions in a patient with severe von Willebrand disease: role of complement and alloantibodies to von Willebrand factor. , 1995, The Journal of laboratory and clinical medicine.

[27]  S. Arkin,et al.  Recombinant Factor VIII for the Treatment of Previously Untreated Patients with Hemophilia A: Safety, Efficacy, and Development of Inhibitors , 1993 .

[28]  S. Arkin,et al.  Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group. , 1993, The New England journal of medicine.

[29]  W. Kreuz,et al.  Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs , 1992, The Lancet.

[30]  P. Salzman,et al.  Lack of Immune Response to Mouse IgG in Hemophilia A Patients Treated Chronically with Monoclate®, a Monoclonal Antibody Affinity Purified Factor VIII Preparation , 1990, Thrombosis and Haemostasis.

[31]  B. Dahlbäck,et al.  Noncoagulation inhibitory factor VIII antibodies after induction of tolerance to factor VIII in hemophilia A patients. , 1990, Blood.

[32]  J. Bove.  Anaphylactic reaction to purified anti‐hemophilic factor concentrate , 1988, Transfusion.

[33]  E. Berntorp,et al.  Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII. , 1988, The New England journal of medicine.

[34]  P. Mannucci,et al.  Life‐threatening reaction to factor VIII concentrate in a patient with severe von Willebrand disease and alloantibodies to von Willebrand factor , 1987, European journal of haematology.

[35]  A. Federici,et al.  Gene deletions correlate with the development of alloantibodies in von Willebrand disease. , 1987, The Journal of clinical investigation.

[36]  M. Maloney,et al.  Desensitization to factor VIII in a patient with classic hemophilia and C2 deficiency. , 1987, Annals of allergy.

[37]  J. Yunginger,et al.  Anaphylactic reactions following infusion of factor VIII in a patient with classic hemophilia. , 1980, The American journal of medicine.

[38]  F. Shakib,et al.  IgG4: a possible mediator of anaphylaxis in a haemophiliac patient , 1979, Clinical allergy.

[39]  P. Mannucci,et al.  Precipitating antibodies in von Willebrand's disease , 1976, Nature.

[40]  D. Green,et al.  Reaction to rapidly infused AHF cryoprecipitate. , 1969, The New England journal of medicine.

[41]  S. Alexander,et al.  Rituximab and desensitization for a patient with severe factor IX deficiency, inhibitors, and history of anaphylaxis. , 2008, Journal of pediatric hematology/oncology.

[42]  Mary E. Martin.  Management of the , 2005 .

[43]  I. Warrier,et al.  Anaphylaxis in Patients with Hemophilia , 2000, Seminars in thrombosis and hemostasis.

[44]  J. Katz,et al.  Factor IX inhibitors and anaphylaxis in hemophilia B. , 1997, Journal of pediatric hematology/oncology.

[45]  N. Ciavarella,et al.  Use of recombinant factor VIIa (NovoSeven) in the treatment of two patients with type III von Willebrand's disease and an inhibitor against von Willebrand factor. , 1996, Haemostasis.

[46]  J. Gill,et al.  Induction of Immune Tolerance in a 7-Year-Old Hemophiliac with an Anaphylactoid Inhibitor , 1995, Thrombosis and Haemostasis.

[47]  P. Mannucci,et al.  Precipitating antibodies to factor VIII/von Willebrand factor in von Willebrand's disease: effects on replacement therapy. , 1981, Blood.